Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANDATE HCT vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Treatment of hypertension,Management of hypertensive urgency (off-label)
Hypertension
Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Labetalol: terminal elimination half-life is 6-8 hours (range 3-16 hours) consistent with twice-daily dosing. Hydrochlorothiazide: terminal half-life 9-10 hours (range 6-15 hours), prolonged in renal impairment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Labetalol is extensively metabolized primarily via glucuronidation (direct conjugation) and minor CYP2D6-mediated oxidation to an inactive metabolite. Hydrochlorothiazide is not metabolized; it is excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Labetalol is primarily excreted in urine as unchanged drug (approximately 55-60%) and as glucuronide conjugates. About 12-27% is excreted in feces via biliary elimination. Hydrochlorothiazide is excreted unchanged in urine (≥95%) via renal tubular secretion. Total renal elimination of labetalol: ~55-60% unchanged; HCTZ: ~95% unchanged.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Labetalol: ~50% bound to albumin. Hydrochlorothiazide: ~40-68% bound to albumin and alpha-1-acid glycoprotein.
~90%, primarily to albumin
Labetalol: Vd 3-16 L/kg (mean 11 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: Vd 0.8-1.5 L/kg (mean 1 L/kg), limited distribution.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Labetalol: oral bioavailability is 25-40% due to extensive first-pass metabolism. Hydrochlorothiazide: oral bioavailability is 65-75% (fasted).
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-90 m L/min: No adjustment. GFR <30 m L/min: Contraindicated due to hydrochlorothiazide component.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: Use with caution; reduce labetalol dose. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism of labetalol.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended; safety and efficacy not established for labetalol/hydrochlorothiazide combination.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lowest dose (100/25 mg daily); titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Beta-blocker withdrawal: abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease. Bronchospasm: avoid in patients with bronchial asthma or COPD. Heart failure: caution in patients with decompensated heart failure; may precipitate worsening. Peripheral vascular disease: may worsen symptoms. Hepatic impairment: labetalol is hepatically metabolized; use caution. Renal impairment: hydrochlorothiazide may be ineffective with Cr Cl <30 m L/min. Electrolyte disturbances: monitor potassium, sodium, magnesium; risk of hypokalemia, hyponatremia, hypomagnesemia. Hyperuricemia: can precipitate gout. Photosensitivity: with hydrochlorothiazide. Exacerbation of systemic lupus erythematosus: reported with thiazides. DM: beta-blockers may mask hypoglycemia. Surgery: withdrawal before elective surgery recommended.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Absolute: sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to labetalol, hydrochlorothiazide, or sulfonamide-derived drugs, anuria. Relative: diabetes mellitus, hyperthyroidism, pheochromocytoma (labetalol may paradoxically elevate blood pressure), severe renal impairment (Cr Cl <30 m L/min for thiazide efficacy).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheese, cured meats, fermented soy products) due to potential hypertensive crises. Limit caffeine intake; may increase heart rate. Avoid excessive potassium-rich foods or supplements unless monitored due to hydrochlorothiazide's potassium-wasting effect. Take with food to reduce GI upset.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, hypoglycemia, and respiratory depression; intrauterine growth restriction reported with chronic use.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Labetalol is excreted into breast milk in low amounts (M/P ratio ~0.6-0.8); generally considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No standard dose adjustment required; however, pregnancy may alter labetalol pharmacokinetics (increased clearance, decreased half-life) potentially necessitating dose titration based on clinical response.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Trandate HCT combines labetalol (alpha/beta blocker) and hydrochlorothiazide. Monitor heart rate, blood pressure, and electrolytes. Avoid in asthma, COPD, bradycardia, heart block, and anuria. Taper if discontinuing. May mask hypoglycemia in diabetics. Can cause orthostatic hypotension; dose at bedtime initially.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed, usually once daily, with or without food.,Do not stop suddenly; tapering is necessary to avoid rebound hypertension.,May cause dizziness or lightheadedness; rise slowly from sitting or lying.,Avoid alcohol; it can worsen dizziness and side effects.,Inform your doctor if you experience slow heartbeat, fainting, swelling of feet/ankles, or unusual weight gain.,May cause photosensitivity; use sunscreen and protective clothing.,Monitor blood pressure regularly at home.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANDATE HCT vs ALDORIL 15, answered by our medical review team.
TRANDATE HCT is a Antihypertensive Combination that works by TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANDATE HCT and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANDATE HCT is: Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANDATE HCT and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANDATE HCT is classified as Category C. First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.